Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - HC Wainwright lifted their FY2026 EPS estimates for shares of Scholar Rock in a report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($3.23) per share for the year, up from their prior estimate of ($3.30). HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock's Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($1.39) EPS, FY2029 earnings at ($0.12) EPS and FY2030 earnings at $1.00 EPS.
Several other research firms have also commented on SRRK. Wedbush reissued an "outperform" rating and set a $64.00 price objective on shares of Scholar Rock in a research note on Tuesday, September 15th. TD Cowen reiterated a "buy" rating on shares of Scholar Rock in a research note on Monday, September 14th. Barclays cut shares of Scholar Rock from an "overweight" rating to a "cautious" rating in a report on Tuesday, September 15th. Jefferies Financial Group raised their target price on Scholar Rock from $57.00 to $65.00 and gave the stock a "buy" rating in a research report on Monday, September 14th. Finally, BMO Capital Markets boosted their price objective on shares of Scholar Rock from $76.00 to $84.00 and gave the company an "outperform" rating in a research report on Monday, September 14th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $67.67.
Read Our Latest Research Report on SRRK
Scholar Rock Trading Down 2.9%
SRRK opened at $46.60 on Thursday. The stock has a market cap of $5.68 billion, a PE ratio of -13.87 and a beta of 0.78. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average of $46.64 and a 200-day moving average of $48.23. Scholar Rock has a 52 week low of $29.35 and a 52 week high of $61.76.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $0.57 million during the quarter, compared to analysts' expectations of $0.30 million. During the same quarter last year, the business earned ($0.90) earnings per share.
Institutional Investors Weigh In On Scholar Rock
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Scholar Rock during the second quarter valued at about $522,175,000. Redmile Group LLC boosted its stake in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company's stock worth $445,715,000 after acquiring an additional 3,845,775 shares during the period. Jennison Associates LLC grew its position in shares of Scholar Rock by 19.5% during the first quarter. Jennison Associates LLC now owns 3,340,492 shares of the company's stock worth $164,219,000 after purchasing an additional 545,304 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of Scholar Rock during the second quarter worth about $123,279,000. Finally, Janus Henderson Group PLC raised its stake in Scholar Rock by 26.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company's stock valued at $109,891,000 after purchasing an additional 462,669 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.
Insider Buying and Selling at Scholar Rock
In other news, Director Srinivas Akkaraju bought 146,970 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were bought at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the purchase, the director owned 6,380,517 shares in the company, valued at $265,365,702.03. This represents a 2.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 10.30% of the company's stock.
Key Scholar Rock News
Here's some of the latest news about SRRK:
- Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to a loss of $0.75 from $0.78 and its FY2026 forecast to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. Analyst outlook
- Positive Sentiment: Scholar Rock’s Q3 loss of $0.81 per share was narrower than the cited consensus estimate, and the company reported its first product revenue—potentially signaling early commercial progress. Q3 results
- Negative Sentiment: HC Wainwright sharply reduced EPS estimates for FY2027–FY2030: its FY2027 loss estimate increased to $2.66 from $1.95, and it moved FY2029 from projected earnings of $0.47 to a loss of $0.12. Its FY2030 profit estimate was cut to $1.00 from $1.44. These weaker longer-term expectations may weigh on the outlook despite the retained Buy rating.
About Scholar Rock
(
Get Free Report)
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company's lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients' motor function.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scholar Rock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.
While Scholar Rock currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.